Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seclidemstat - Salarius Pharmaceuticals

Next Previous
X
Search
Drug Profile

Seclidemstat - Salarius Pharmaceuticals

Alternative Names: SP-2577; SP-2577 mesylate

Latest Information Update: 28 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Utah Research Foundation
  • Developer M. D. Anderson Cancer Center; Salarius Pharmaceuticals; The Ivy Brain Tumor Center; Translational Genomics Research Institute
  • Class Antineoplastics; Benzoic acids; Hydrazines; Piperazines; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Chronic myelomonocytic leukaemia; Ewing's sarcoma; Myelodysplastic syndromes; Myxoid liposarcoma; Sarcoma; Solid tumours
  • Preclinical Gynaecological cancer; Small cell lung cancer
  • No development reported Adrenocortical carcinoma; Glioblastoma

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in Adrenocortical-carcinoma in USA
  • 18 Jun 2024 Updated efficacy and adverse events data from a phase I/II trial in myelodysplastic syndromes and chronic myelomonocytic leukemia released by Salarius Pharmaceuticals
  • 13 Jun 2024 Updated efficacy and safety data from the phase I/II trial in Myelodysplastic syndromes presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top